Treatment guidelines for HIV-associated wasting.
Polsky
Bruce
B
Department of Medicine, Division of Infectious Diseases, St. Luke's-Roosevelt Hospital Center, New York, NY, USA.
Kotler
Donald
D
Steinhart
Corklin
C
D045930:Anabolic Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods; D001823:Body Composition; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000628:therapy; D019247:HIV Wasting Syndrome / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D006801:Humans; D008297:Male; D009277:Nandrolone / Q000627:therapeutic use; D009752:Nutritional Status; D010074:Oxandrolone / Q000627:therapeutic use
D045930:Anabolic Agents; D009277:Nandrolone; D010074:Oxandrolone